SEC Comment Letter 0000000000-25-003762 to ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc.
Date: April 8, 2025 · CIK: 0001859007 · Accession: 0000000000-25-003762
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286396
Letter
Re: ZyVersa Therapeutics, Inc. Registration Statement on Form S-3 Filed April 4, 2025 File No. 333-286396 Dear Stephen C. Glover:
April 8, 2025
Stephen C. Glover Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Faith L. Charles, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 8, 2025 Stephen C. Glover Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Re: ZyVersa Therapeutics, Inc. Registration Statement on Form S-3 Filed April 4, 2025 File No. 333-286396 Dear Stephen C. Glover: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Faith L. Charles, Esq. </TEXT> </DOCUMENT>